Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced the completion of enrollment for a global Phase III study of its pipeline candidate OT-101. The randomized, double-blind, placebo-controlled, multi-center trial aims to assess the efficacy and safety of OT-101 in treating myopia in children. The study has enrolled 170 subjects, marking a significant milestone in the development of this innovative treatment.
OT-101: Innovation in Atropine Delivery
OT-101 is a low-concentration atropine solution designed to control myopia progression, a condition that currently lacks stable and commercially available treatments. Traditional low-concentration atropine solutions face challenges related to instability, which OT-101 addresses through its innovative closed split device. This delivery system maintains the medication’s environment as close to the standard as possible, ensuring consistent efficacy and safety.
Enhanced Comfort and Compliance
By maintaining the appropriate pH value, OT-101 is expected to offer improved comfort for users, potentially leading to better treatment compliance. Currently, there are no commercially available low-concentration atropine ophthalmic preparations in mainstream markets globally. Ocumension’s OT-101 aims to fill this gap by providing a stable and effective solution for controlling myopia progression in children.-Fineline Info & Tech
